The Royal Swedish Academy of Sciences awarded Sir Gregory P. Winter the 2018 Nobel Prize in Chemistry for revolutionizing both chemistry and the development of new pharmaceuticals through directed evolution. He was lauded for his work using phage display for the directed evolution of antibodies and peptides to produce new medicines. Winter shares the Nobel Prize with Frances Arnold and George Smith.
Winter is Master of Trinity College, Cambridge, a fellow of the Royal Society, and was knighted in 2004 for services to science. He is also the founder and Board member of Goodwin client Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform.
“The 2018 Nobel Laureates in Chemistry have taken control of evolution and used it for purposes that bring the greatest benefit to humankind. Enzymes produced through directed evolution are used to manufacture everything from biofuels to pharmaceuticals. Antibodies evolved using a method called phage display can combat autoimmune diseases and in some cases cure metastatic cancer,” noted The Nobel Assembly.
Please join us in congratulating Sir Gregory Winter on this distinguished honor and the team at Bicycle Therapeutics for transforming this scientific achievement into advanced therapeutics.